Skip to main content

Has inotuzumab ozogamicin been funded by Pharmac for the treatment of relapsed or refractory CD22-positive precursor B-cell acute lymphoblastic leukaemia, if not, is it under consideration for funding?

Answered Question 18912 (2026)
Question published
Reply lodged
Bookmark

Asked by

Ayesha Verrall

List MP · Labour Party

Question

  • Has inotuzumab ozogamicin been funded by Pharmac for the treatment of relapsed or refractory CD22-positive precursor B-cell acute lymphoblastic leukaemia, if not, is it under consideration for funding?

Answered by

Hon David Seymour

Member for Epsom · ACT Party · Associate Minister of Health

Answer

Yes, inotuzumab ozogamicin is funded by Pharmac for the treatment of relapsed or refractory CD22 positive precursor B cell acute lymphoblastic leukaemia. I am advised by Pharmac that it has been funded since 1 April 2025. I refer the Member to the following link for more information: https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-03-decision-to-fund-new-medicines-for-cancer-and-infections-and-to-change-the-funded-brand-of-palbociclib